Marché mondial de l’anémie hémolytique acquise (auto-immune) – Tendances et prévisions de l’industrie jusqu’en 2029

Analyse et taille du marché                              

L'anémie hémolytique est un type d'anémie qui survient lorsque vos globules rouges se décomposent ou meurent plus vite que votre corps ne peut les remplacer par de nouveaux. L'anémie hémolytique peut être causée par des troubles génétiques héréditaires provoquant une anémie, des infections ou des médicaments spécifiques. Le traitement de l'anémie hémolytique varie en fonction de l'origine de la maladie. Les transfusions sanguines, les corticostéroïdes et le rituximab sont tous des traitements possibles. Une intervention chirurgicale pour enlever la rate est recommandée dans les cas plus graves. L'anémie hémolytique à anticorps chauds et l'anémie hémolytique à anticorps froids sont deux types d'anémie hémolytique acquise (auto-immune). Les auto-anticorps se fixent aux globules rouges dans l'anémie hémolytique à anticorps chauds et les détruisent à une température supérieure à la température corporelle ; dans l'anémie hémolytique à anticorps froids, les anticorps auto-générés tuent les globules rouges à une température inférieure à la température corporelle.

Français Data Bridge Market Research analyse que le marché de l’anémie hémolytique acquise (auto-immune) était évalué à 676,75 millions USD en 2021 et devrait atteindre 992,28 millions USD d’ici 2029, enregistrant un TCAC de 4,90 % au cours de la période de prévision de 2022 à 2029. En plus des informations sur le marché telles que la valeur du marché, le taux de croissance, les segments de marché, la couverture géographique, les acteurs du marché et le scénario du marché, le rapport de marché organisé par l’équipe de recherche sur le marché Data Bridge comprend également une analyse approfondie des experts, une épidémiologie des patients, une analyse du pipeline, une analyse des prix et un cadre réglementaire.

Portée du rapport et segmentation du marché

Définition du marché

L'anémie hémolytique acquise non génétique (auto-immune) survient lorsque le système immunitaire de l'organisme élimine les tissus sains en réponse à des organismes envahissants tels que les lymphocytes et les anticorps. Le traitement se concentre sur trois objectifs principaux : prévenir la destruction des globules rouges, augmenter le nombre de globules rouges et traiter la maladie sous-jacente. Les principales options de traitement comprennent les transfusions sanguines, les médicaments, la plasmaphérèse et les procédures. Pour traiter l'anémie hémolytique acquise (auto-immune), des médicaments tels que la prednisone, le rituximab, l'hydroxyurée et la cyclosporine sont couramment utilisés.

Dynamique du marché de l'anémie hémolytique acquise (auto-immune)

Conducteurs

• Prévalence croissante de l'anémie ferriprive

La prévalence croissante de l'anémie ferriprive devrait influencer le taux de croissance du marché. Parallèlement à cela, l'incidence croissante des maladies auto-immunes telles que le lupus, la polyarthrite rhumatoïde , le syndrome de Sjögren, les maladies thyroïdiennes, la maladie de Hashimoto et la colite ulcéreuse influenceront la dynamique du marché au cours de la période de prévision.

• Augmenter les investissements dans les infrastructures de santé

Un autre facteur important qui influence le taux de croissance du marché de l’anémie hémolytique acquise (auto-immune) est l’augmentation des dépenses de santé, ce qui contribue à améliorer son infrastructure. En outre, diverses organisations gouvernementales visent à améliorer l’infrastructure des soins de santé en augmentant le financement, ce qui influencera davantage la dynamique du marché.

• Augmentation du nombre de personnes âgées

The increasing number of geriatric population is estimated to enhance the market's growth rate. According to the World Ageing 2020 estimate, there will be 727 million people aged 65 and up in the year 2020. In 2050, this population is expected to increase to 1.5 billion. The proportion of the geriatric population is estimated to rise. The elderly population is more prone to acquired (autoimmune) hemolytic anemia, further enhancing the market's growth rate. Acquired (autoimmune) hemolytic anemia can affect people of all ages and genders, though it most commonly occurs in females over the age of 40.

Furthermore, a surging number of government initiatives to spread awareness and sedentary lifestyle will result in the expansion of acquired (autoimmune) hemolytic anemia market. Along with this, rising level of disposable income and increase in the risk of haemodilution will enhance the market's growth rate.

Opportunities

• Rise in R&D activities  

The market's growth is fueled by growing number of research and development activities. This will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.

Moreover, the market's growth is fueled by investment to develop advanced technologies and increase the number of emerging markets. These factors will provide beneficial opportunities for the acquired (autoimmune) hemolytic anemia market growth.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the growth rate of the acquired (autoimmune) hemolytic anemia market during 2022-2029. The lack of healthcare infrastructure in developing economies and the dearth of skilled professionals will challenge the acquired (autoimmune) hemolytic anemia market. Additionally, lack of awareness among people and poor reimbursement policies will restrain and further impede the market's growth rate during the forecast period of 2022-2029.

This acquired (autoimmune) hemolytic anemia market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the acquired (autoimmune) hemolytic anemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Autoimmune hemolytic anemia is rare, affecting approximately 1 to 2 of every 100,000 people yearly.

The acquired (autoimmune) hemolytic anemia market also provides detailed market analysis for patient analysis, prognosis, and cures. Prevalence, incidence, mortality, and adherence rates are some data variables available in the report. Direct or indirect impact analyses of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period. 

COVID-19 Impact on Acquired (Autoimmune) Hemolytic Anemia Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for various reasons, including difficulty accessing a doctor, fear of infection transmission, inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of acquired (autoimmune) hemolytic anemia in recent months.

Recent Development

• In February 2022, The U.S. Food and Drug Administration (FDA) announced the approval of Enjaymo (sutimlimab-jome). It decreases red blood cell transfusion requirement due to hemolysis in adults with cold agglutinin disease (CAD). Enjaymo is the first as well as only approved treatment for people with CAD and functions by inhibiting the destruction of red blood cells (hemolysis).

Global Acquired (Autoimmune) Hemolytic Anemia Market Scope

The acquired (autoimmune) hemolytic anemia market is segmented on the basis of types, treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Types

• Warm Autoimmune Induced Hemolytic Anemia
• Cold Agglutinin Disease (CAD)
• Others

Treatment

• Medication
• Corticosteroids
• Immunosuppressive agents
• Others
• Blood Transfusion
• Surgery
• Splenectomy
• Others

Diagnosis

• Blood Tests
• Coombs Test
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Acquired (Autoimmune) Hemolytic Anemia Market Regional Analysis/Insights

The acquired (autoimmune) hemolytic anemia market is analyzed and market size insights and trends are provided by country, types, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the acquired (autoimmune) hemolytic anemia market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America and Europe dominate the acquired (autoimmune) hemolytic anemia market because of the well-established healthcare infrastructure in this region. Additionally, the growing focus of major key players on novel technology will further propel the market's growth rate in this region.

Asia-Pacific is expected to be the fastest-growing region during the forecast period of 2022-2029 due to the growing number of patient populations and the large number of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Acquired (Autoimmune) Hemolytic Anemia Market Share Analysis

The acquired (autoimmune) hemolytic anemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to acquired (autoimmune) hemolytic anemia market.

Some of the major players operating in the acquired (autoimmune) hemolytic anemia market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd.(Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• AbbVie Inc. (U.S.)
• Fresenius SE & Co. KGaA (Germany)
• Lupin (India)
• ViforPharma Ltd. (Switzerland)
• AMAG Pharmaceuticals (U.S.)
• Akebia Therapeutics, INC. (États-Unis)
• CHO-A Pharmaceutical CO., LTD. (Corée du Sud)
• Orion Corporation (Finlande)
• Pharmacosmos A/S (Danemark)
• Shield Therapeutics (Royaume-Uni)
• Advanz Pharmaceutical (Royaume-Uni)
• Alkem Labs (Inde)
• Zydus Cadila (Inde)
• Hikma Pharmaceuticals PLC (Royaume-Uni)

SKU-53441